Giant cell tumor of bone: A basic science perspective

Bone

Volumn 52, Issue 1, 2013, Pages 238-246

  Cowan, Robert W ^a   Singh, Gurmit ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bone; Giant cell tumor; Matrix metalloproteinase; Osteoclastogenesis; RANKL; Resorption

Indexed keywords

CATHEPSIN K; CCAAT ENHANCER BINDING PROTEIN BETA; CD33 ANTIGEN; CD68 ANTIGEN; CELL PROTEIN; COLLAGEN; COLLAGENASE 3; COLONY STIMULATING FACTOR 1; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; DENOSUMAB; GELATINASE A; GELATINASE B; HEMOSIDERIN; MATRIX METALLOPROTEINASE; NUCLEAR FACTOR OF ACTIVATED T CELLS C1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN MDM2; PROTEIN P53; TELOMERASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

BIOLOGICAL MODEL; BLEEDING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CHROMOSOME ABERRATION; COLLAGEN SYNTHESIS; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GIANT CELL; LUNG METASTASIS; MESENCHYMAL STROMA CELL; MOLECULAR CLONING; MONOCYTE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOCLASTOMA; OSTEOLYSIS; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANKL GENE; REVIEW; TELOMERE HOMEOSTASIS; TUMOR VASCULARIZATION; UBIQUITINATION; UCHL1 GENE;

BONE RESORPTION; GIANT CELL TUMOR OF BONE; HUMANS;

EID: 84868229928     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.10.002     Document Type: Review

References (194)

1. Gupta R., Seethalakshmi V., Jambhekar N.A., Prabhudesai S., Merchant N., Puri A., et al. Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol 2008, 12:239-248.
2. Unni K.K., Inwards C.Y. Giant cell tumor (osteoclastoma). Dahlin's bone tumors: general aspects and data on 10,165 cases 2010, 225-242. Lippincott Williams & Wilkins, New York.
3. Tubbs W.S., Brown L.R., Beabout J.W., Rock M.G., Unni K.K. Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases. AJR Am J Roentgenol 1992, 158:331-334.
4. Viswanathan S., Jambhekar N.A. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities?. Clin Orthop Relat Res 2010, 468:827-833.
5. Alacacioǧlu A., Bengi G., Öztop I., Canda T., Balci P., Osma E., et al. Metastasis of giant cell tumor to the breast: case report and review of the literature. Tumori 2006, 92:351-353.
6. Zhang Q., Zhao H., Maheshwari A.V., Cai L., Yu F., Niu X. Isolated cardiac metastasis from a histologically "benign" giant-cell tumor of the distal end of the femur: a case report. J Bone Joint Surg Am 2010, 92:2725-2731.
7. Tyler W., Barrett T., Frassica F., McCarthy E. Skin metastasis from conventional giant cell tumor of bone: conceptual significance. Skeletal Radiol 2002, 31:166-170.
8. Connell D., Munk P.L., Lee M.J., O'Connell J.X., Janzen D., Vu M., et al. Giant cell tumor of bone with selective metastases to mediastinal lymph nodes. Skeletal Radiol 1998, 27:341-345.
9. Errani C., Ruggieri P., Asenzio M.A., Toscano A., Colangeli S., Rimondi E., et al. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 2010, 36:1-7.
10. Prosser G.H., Baloch K.G., Tillman R.M., Carter S.R., Grimer R.J. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?. Clin Orthop Relat Res 2005, 435:211-218.
11. Turcotte R.E., Wunder J.S., Isler M.H., Bell R.S., Schachar N., Masri B.A., et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002, 397:248-258.
12. Balke M., Campanacci L., Gebert C., Picci P., Gibbons M., Taylor R., et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer 2010, 10:462.
13. Tse L.F., Wong K.C., Kumta S.M., Huang L., Chow T.C., Griffith J.F. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008, 42:68-73.
14. Thomas D., Henshaw R., Skubitz K., Chawla S., Staddon A., Blay J.Y., et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.
15. Goldring S.R., Roelke M.S., Petrison K.K., Bhan A.K. Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest 1987, 79:483-491.
16. Wülling M., Delling G., Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol 2003, 34:983-993.
17. Byers V.S., Levin A.S., Johnston J.O., Hackett A.J. Quantitative immunofluorescence studies of the tumor antigen-bearing cell in giant cell tumor of bone and osteogenic sarcoma. Cancer Res 1975, 35:2520-2531.
18. Lan J, Liu X, Rong W, Wei F, Jiang L, Yu H et al. Stro-1(+) stromal cells have stem-like features in giant cell tumor of bone. J Surg Oncol 2012: in press; doi: doi:10.1002/jso.23151.
19. Ghert M., Simunovic N., Cowan R.W., Colterjohn N., Singh G. Properties of the stromal cell in giant cell tumor of bone. Clin Orthop Relat Res 2007, 459:8-13.
20. Hasegawa T., Hirose T., Seki K., Sano T., Hizawa K. Transforming growth factor alpha and CD68 immunoreactivity in giant cell tumours of bone: a study on the nature of stromal and giant cells, and their interrelations. J Pathol 1993, 170:305-310.
21. Huang L., Teng X.Y., Cheng Y.Y., Lee K.M., Kumta S.M. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone 2004, 34:393-401.
22. Murata A., Fujita T., Kawahara N., Tsuchiya H., Tomita K. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 2005, 10:581-588.
23. Nishimura M., Yuasa K., Mori K., Miyamoto N., Ito M., Tsurudome M., et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J Orthop Res 2005, 23:979-987.
24. Robinson D., Segal M., Nevo Z. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. Pathobiology 2002, 70:333-342.
25. Salerno M., Avnet S., Alberghini M., Giunti A., Baldini N. Histogenetic characterization of giant cell tumor of bone. Clin Orthop Relat Res 2008, 466:2081-2091.
26. Alberghini M., Kliskey K., Krenacs T., Picci P., Kindblom L., Forsyth R., et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 2010, 456:97-103.
27. Bardi G., Pandis N., Mandahl N., Heim S., Sfikas K., Willén H., et al. Chromosomal abnormalities in giant cell tumors of bone. Cancer Genet Cytogenet 1991, 57:161-167.
28. James I.E., Dodds R.A., Olivera D.L., Nuttall M.E., Gowen M. Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res 1996, 11:1453-1460.
29. Joyner C.J., Quinn J.M., Triffitt J.T., Owen M.E., Athanasou N.A. Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumour of bone. Bone Miner 1992, 16:37-48.
30. Kubota K., Sakikawa C., Katsumata M., Nakamura T., Wakabayashi K. Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res 2002, 17:257-265.
31. Galvin R.J., Cullison J.W., Avioli L.V., Osdoby P.A. Influence of osteoclasts and osteoclast-like cells on osteoblast alkaline phosphatase activity and collagen synthesis. J Bone Miner Res 1994, 9:1167-1178.
32. Branstetter D., Nelson S.D., Manivel J.C., Blay J.Y., Chawla S., Thomas D.M., et al. Denosumab induces tumor reduction and bone formation in patients with giant cell tumor of bone. Clin Cancer Res 2012, 18:4415-4424.
33. Bridge J.A., Neff J.R., Bhatia P.S., Sanger W.G., Murphey M.D. Cytogenetic findings and biologic behavior of giant cell tumors of bone. Cancer 1990, 65:2697-2703.
34. Bridge J.A., Neff J.R., Mouron B.J. Giant cell tumor of bone. Chromosomal analysis of 48 specimens and review of the literature. Cancer Genet Cytogenet 1992, 58:2-13.
35. Gorunova L., Vult von Steyern F., Storlazzi C.T., Bjerkehagen B., Follerås G., Heim S., et al. Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations. Genes Chromosomes Cancer 2009, 48:583-602.
36. Schwartz H.S., Jenkins R.B., Dahl R.J., Dewald G.W. Cytogenetic analyses on giant-cell tumors of bone. Clin Orthop Relat Res 1989, 240:250-260.
37. Moskovszky L., Szuhai K., Krenács T., Hogendoorn P.C., Szendröi M., Benassi M.S., et al. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer 2009, 48:468-479.
38. Zheng M.H., Siu P., Papadimitriou J.M., Wood D.J., Murch A.R. Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone. Pathology 1999, 31:373-378.
39. Schajowicz F., Cabrini R.L., Gimenez I. Microspectrophotometric quantitation of DNA in bone tumors with giant cells (osteoclastoma, osteosarcoma and chondroblastoma). Clin Orthop Relat Res 1981, 156:91-97.
40. Sawyer J.R., Goosen L.S., Binz R.L., Swanson C.M., Nicholas R.W. Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone. Cancer Genet Cytogenet 2005, 159:32-36.
41. Gebre-Medhin S., Broberg K., Jonson T., Gorunova L., von Steyern F.V., Brosjö O., et al. Telomeric associations correlate with telomere length reduction and clonal chromosome aberrations in giant cell tumor of bone. Cytogenet Genome Res 2009, 124:121-127.
42. Forsyth R.G., De Boeck G., Bekaert S., De Meyer T., Taminiau A.H., Uyttendaele D., et al. Telomere biology in giant cell tumour of bone. J Pathol 2008, 214:555-563.
43. Schwartz H.S., Juliao S.F., Sciadini M.F., Miller L.K., Butler M.G. Telomerase activity and oncogenesis in giant cell tumor of bone. Cancer 1995, 75:1094-1099.
44. Wu Y., Hsiu J., Lou Y., Xia Z., Somers K. p53 protein accumulation and genetic alterations in human giant cell tumors of bone (osteoclastomas). Int J Oncol 1997, 10:1087-1092.
45. de Souza P.E., Paim J.F., Carvalhais J.N., Gomez R.S. Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor. J Oral Pathol Med 1999, 28:54-58.
46. Pompetti F., Rizzo P., Simon R.M., Freidlin B., Mew D.J., Pass H.I., et al. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 1996, 63:37-50.
47. Ueda Y., Dockhorn-Dworniczak B., Blasius S., Mellin W., Wuisman P., Böcker W., et al. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 1993, 119:172-178.
48. Osaka S., Sugita H., Osaka E., Yoshida Y., Ryu J., Hemmi A., et al. Clinical and immunohistochemical characteristics of benign giant cell tumour of bone with pulmonary metastases: case series. J Orthop Surg 2004, 12:55-62. (Hong Kong).
49. Masui F., Ushigome S., Fujii K. Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Pathol Int 1998, 48:723-729.
50. Oda Y., Sakamoto A., Saito T., Matsuda S., Tanaka K., Iwamoto Y., et al. Secondary malignant giant-cell tumour of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation. Histopathology 2001, 39:629-637.
51. Papanastassiou I., Ioannou M., Papagelopoulos P.J., Arealis G., Mihas C., Iakovidou I., et al. P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study. Orthopedics 2010, 33.
52. Saito T., Mitomi H., Izumi H., Suehara Y., Okubo T., Torigoe T., et al. A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up. Hum Pathol 2011, 42:727-733.
53. Saito T., Mitomi H., Suehara Y., Okubo T., Torigoe T., Takagi T., et al. A case of de novo secondary malignant giant-cell tumor of bone with loss of heterozygosity of p53 gene that transformed within a short-term follow-up. Pathol Res Pract 2011, 207:664-669.
54. Gong L., Liu W., Sun X., Sajdik C., Tian X., Niu X., et al. Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch 2012, 460:327-334.
55. Cai G., Ramdall R., Garcia R., Levine P. Pulmonary metastasis of giant cell tumor of the bone diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol 2007, 35:358-362.
56. Evdokiou A., Atkins G.J., Bouralexis S., Hay S., Raggatt L.J., Cowled P.A., et al. Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone. Int J Oncol 2001, 19:625-632.
57. Fellenberg J., Lehner B., Witte D. Silencing of the UCHL1 gene in giant cell tumors of bone. Int J Cancer 2010, 127:1804-1812.
58. Li L., Tao Q., Jin H., van Hasselt A., Poon F.F., Wang X., et al. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res 2010, 16:2949-2958.
59. Radaelli E., Rustighi A., Scanziani E. Giant cell tumor of bonelike lesion in a Trp53 mutant mouse. Toxicol Pathol 2012, 40:675-681.
60. Steinman H.A., Burstein E., Lengner C., Gosselin J., Pihan G., Duckett C.S., et al. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 2004, 279:4877-4886.
61. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996, 271:12511-12516.
62. Grano M., Mori G., Minielli V., Cantatore F.P., Colucci S., Zallone A.Z. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. Biochem Biophys Res Commun 2000, 270:1097-1100.
63. Knowles H.J., Athanasou N.A. Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis. J Pathol 2009, 218:256-264.
64. Zheng M.H., Fan Y., Wysocki S., Wood D.J., Papadimitriou J.M. Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization. J Bone Miner Res 1993, 8:113-118.
65. Myers D.E., Collier F.M., Minkin C., Wang H., Holloway W.R., Malakellis M., et al. Expression of functional RANK on mature rat and human osteoclasts. FEBS Lett 1999, 463:295-300.
66. Anazawa U., Hanaoka H., Shiraishi T., Morioka H., Morii T., Toyama Y. Similarities between giant cell tumor of bone, giant cell tumor of tendon sheath, and pigmented villonodular synovitis concerning ultrastructural cytochemical features of multinucleated giant cells and mononuclear stromal cells. Ultrastruct Pathol 2006, 30:151-158.
67. Mii Y., Miyauchi Y., Morishita T., Miura S., Honoki K., Aoki M., et al. Osteoclast origin of giant cells in giant cell tumors of bone: ultrastructural and cytochemical study of six cases. Ultrastruct Pathol 1991, 15:623-629.
68. Lindeman J.H., Hanemaaijer R., Mulder A., Dijkstra P.D., Szuhai K., Bromme D., et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004, 165:593-600.
69. Inaoka T., Bilbe G., Ishibashi O., Tezuka K., Kumegawa M., Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995, 206:89-96.
70. Littlewood-Evans A., Kokubo T., Ishibashi O., Inaoka T., Wlodarski B., Gallagher J.A., et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 1997, 20:81-86.
71. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11:88-95.
72. Atkins G.J., Kostakis P., Vincent C., Farrugia A.N., Houchins J.P., Findlay D.M., et al. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006, 21:1339-1349.
73. Atkins G.J., Haynes D.R., Graves S.E., Evdokiou A., Hay S., Bouralexis S., et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000, 15:640-649.
74. Roux S., Amazit L., Meduri G., Guiochon-Mantel A., Milgrom E., Mariette X. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002, 117:210-216.
75. Collier F.M., Huang W.H., Holloway W.R., Hodge J.M., Gillespie M.T., Daniels L.L., et al. Osteoclasts from human giant cell tumors of bone lack estrogen receptors. Endocrinology 1998, 139:1258-1267.
76. Nicholson G.C., Horton M.A., Sexton P.M., D'Santos C.S., Moseley J.M., Kemp B.E., et al. Calcitonin receptors of human osteoclastoma. Horm Metab Res 1987, 19:585-589.
77. Lau Y.S., Sabokbar A., Gibbons C.L., Giele H., Athanasou N. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005, 36:945-954.
78. Ohsaki Y., Takahashi S., Scarcez T., Demulder A., Nishihara T., Williams R., et al. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology 1992, 131:2229-2234.
79. Kanehisa J., Izumo T., Takeuchi M., Yamanaka T., Fujii T., Takeuchi H. In vitro bone resorption by isolated multinucleated giant cells from giant cell tumour of bone: light and electron microscopic study. Virchows Arch A Pathol Anat Histopathol 1991, 419:327-338.
80. Chambers T.J., Fuller K., McSheehy P.M., Pringle J.A. The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol 1985, 145:297-305.
81. Steiner G.C., Ghosh L., Dorfman H.D. Ultrastructure of giant cell tumors of bone. Hum Pathol 1972, 3:569-586.
82. Zheng M.H., Robbins P., Xu J., Huang L., Wood D.J., Papadimitriou J.M. The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001, 16:297-307.
83. Liao T.S., Yurgelun M.B., Chang S.S., Zhang H.Z., Murakami K., Blaine T.A., et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 2005, 23:203-209.
84. Zheng M.H., Fan Y., Smith A., Wysocki S., Papadimitriou J.M., Wood D.J. Gene expression of monocyte chemoattractant protein-1 in giant cell tumors of bone osteoclastoma: possible involvement in CD68+ macrophage-like cell migration. J Cell Biochem 1998, 70:121-129.
85. Brecher M.E., Franklin W.A., Simon M.A. Immunohistochemical study of mononuclear phagocyte antigens in giant cell tumor of bone. Am J Pathol 1986, 125:252-257.
86. Forsyth R.G., De Boeck G., Baelde J.J., Taminiau A.H., Uyttendaele D., Roels H., et al. CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res 2009, 24:70-77.
87. Laurin S. Angiography in giant cell tumors. Radiologe 1977, 17:118-123.
88. Prando A., deSantos L.A., Wallace S., Murray J.A. Angiography in giant-cell bone tumors. Radiology 1979, 130:323-331.
89. Kumta S.M., Huang L., Cheng Y.Y., Chow L.T., Lee K.M., Zheng M.H. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci 2003, 73:1427-1436.
90. Zheng M.H., Xu J., Robbins P., Pavlos N., Wysocki S., Kumta S.M., et al. Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum Pathol 2000, 31:804-812.
91. Knowles H.J., Athanasou N.A. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol 2008, 215:56-66.
92. Matsumoto Y., Okada Y., Fukushi J., Kamura S., Fujiwara T., Iida K., et al. Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone. J Orthop Surg Res 2010, 5:85.
93. Oreffo R.O., Marshall G.J., Kirchen M., Garcia C., Gallwitz W.E., Chavez J., et al. Characterization of a cell line derived from a human giant cell tumor that stimulates osteoclastic bone resorption. Clin Orthop Relat Res 1993, 296:229-241.
94. Balke M., Neumann A., Szuhai K., Agelopoulos K., August C., Gosheger G., et al. A short-term in vivo model for giant cell tumor of bone. BMC Cancer 2011, 11:241.
95. Miyamoto N., Higuchi Y., Tajima M., Ito M., Tsurudome M., Nishio M., et al. Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. J Orthop Res 2000, 18:647-654.
96. Baud'huin M., Renault R., Charrier C., Riet A., Moreau A., Brion R., et al. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol 2010, 221:77-86.
97. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K., et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kB (RANK) receptors. J Exp Med 1999, 190:1741-1754.
98. Huang L., Xu J., Wood D.J., Zheng M.H. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000, 156:761-767.
99. Morgan T., Atkins G.J., Trivett M.K., Johnson S.A., Kansara M., Schlicht S.L., et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kB. Am J Pathol 2005, 167:117-128.
100. Skubitz K.M., Cheng E.Y., Clohisy D.R., Thompson R.C., Skubitz A.P. Gene expression in giant-cell tumors. J Lab Clin Med 2004, 144:193-200.
101. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., et al. Receptor activator of nuclear factor kB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 2003, 163:2021-2031.
102. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., et al. Involvement of receptor activator of nuclear factor kB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269.
103. Atkins G.J., Bouralexis S., Haynes D.R., Graves S.E., Geary S.M., Evdokiou A., et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 2001, 28:370-377.
104. Massey H.M., Flanagan A.M. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999, 106:167-170.
105. Fujikawa Y., Quinn J.M., Sabokbar A., McGee J.O., Athanasou N.A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996, 137:4058-4060.
106. Cowan R.W., Singh G., Ghert M. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone. J Orthop Res 2012, 30:877-884.
107. Ikeda T., Kasai M., Utsuyama M., Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kB ligand and their differential expression in bone and thymus. Endocrinology 2001, 142:1419-1426.
108. Hikita A., Yana I., Wakeyama H., Nakamura M., Kadono Y., Oshima Y., et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kB ligand. J Biol Chem 2006, 281:36846-36855.
109. Lynch C.C., Hikosaka A., Acuff H.B., Martin M.D., Kawai N., Singh R.K., et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005, 7:485-496.
110. Lum L., Wong B.R., Josien R., Becherer J.D., Erdjument-Bromage H., Schlöndorff J., et al. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999, 274:13613-13618.
111. Sasaguri Y., Komiya S., Sugama K., Suzuki K., Inoue A., Morimatsu M., et al. Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone. Am J Pathol 1992, 141:611-621.
112. Hemingway F., Taylor R., Knowles H.J., Athanasou N.A. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 2011, 48:938-944.
113. Rifas L., Weitzmann M.N. A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum 2009, 60:3324-3335.
114. Itonaga I., Sabokbar A., Sun S.G., Kudo O., Danks L., Ferguson D., et al. Transforming growth factor-β induces osteoclast formation in the absence of RANKL. Bone 2004, 34:57-64.
115. Kim N., Kadono Y., Takami M., Lee J., Lee S.H., Okada F., et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005, 202:589-595.
116. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
117. Gohda J., Akiyama T., Koga T., Takayanagi H., Tanaka S., Inoue J. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 2005, 24:790-799.
118. Ishida N., Hayashi K., Hoshijima M., Ogawa T., Koga S., Miyatake Y., et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002, 277:41147-41156.
119. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004, 279:45969-45979.
120. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004, 279:26475-26480.
121. 3 integrin promoter in osteoclast differentiation. Gene 2006, 372:92-102.
122. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005, 202:1261-1269.
123. Lietman S.A., Prescott N.L., Hicks D.G., Westra W.H., Levine M.A. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism. Clin Orthop Relat Res 2007, 459:22-27.
124. Miyamoto H., Suzuki T., Miyauchi Y., Iwasaki R., Kobayashi T., Sato Y., et al. Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells. J Bone Miner Res 2012, 27:1289-1297.
125. Mensah K.A., Ritchlin C.T., Schwarz E.M. RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens. J Cell Physiol 2010, 223:76-83.
126. Chiu Y.H., Mensah K.A., Schwarz E.M., Ju Y., Takahata M., Feng C., et al. Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res 2012, 27:79-92.
127. Yagi M., Miyamoto T., Sawatani Y., Iwamoto K., Hosogane N., Fujita N., et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005, 202:345-351.
128. Tian B.L., Wen J.M., Zhang M., Xie D., Xu R.B., Luo C.J. The expression of ADAM12 (meltrin α) in human giant cell tumours of bone. Mol Pathol 2002, 55:394-397.
129. Abe E., Mocharla H., Yamate T., Taguchi Y., Manolagas S.C. Meltrin-α, a fusion protein involved in multinucleated giant cell and osteoclast formation. Calcif Tissue Int 1999, 64:508-515.
130. Smink J.J., Tunn P.U., Leutz A. Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ-MafB axis. J Mol Med (Berl) 2012, 90:25-30.
131. Smink J.J., Bégay V., Schoenmaker T., Sterneck E., de Vries T.J., Leutz A. Transcription factor C/EBPβ isoform ratio regulates osteoclastogenesis through MafB. EMBO J 2009, 28:1769-1781.
132. Ng P.K., Tsui S.K., Lau C.P., Wong C.H., Wong W.H., Huang L., et al. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem 2010, 110:438-446.
133. Kartsogiannis V., Zhou H., Horwood N.J., Thomas R.J., Hards D.K., Quinn J.M., et al. Localization of RANKL (receptor activator of NFkB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999, 25:525-534.
134. Kandel R., Li S.Q., Bell R., Wunder J., Ferguson P., Kauzman A., et al. Cyclin D1 and p21 is elevated in the giant cells of giant cell tumors. J Orthop Res 2006, 24:428-437.
135. Kauzman A., Li S.Q., Bradley G., Bell R.S., Wunder J.S., Kandel R. Cyclin alterations in giant cell tumor of bone. Mod Pathol 2003, 16:210-218.
136. Kawaguchi K., Oda Y., Saito T., Yamamoto H., Takahira T., Tamiya S., et al. Decreased expression of transforming growth factor-β II receptor is associated with that of p27KIP1 in giant cell tumor of bone: a possible link between transforming growth factor-β and cell cycle-related protein. Hum Pathol 2004, 35:61-68.
137. Matsubayashi S., Nakashima M., Kumagai K., Egashira M., Naruke Y., Kondo H., et al. Immunohistochemical analyses of β-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract 2009, 205:626-633.
138. Cowan R.W., Singh G., Ghert M. The role of parathyroid hormone-related protein in giant cell tumour of bone. Bone 2011, 48:S48.
139. Nakashima M., Nakayama T., Ohtsuru A., Fukada E., Niino D., Yamazumi K., et al. Expression of parathyroid hormone (PTH)-related peptide (PthrP) and PTH/PTHrP receptor in osteoclast-like giant cells. Pathol Res Pract 2003, 199:85-92.
140. Langub M.C., Monier-Faugere M.C., Qi Q., Geng Z., Koszewski N.J., Malluche H.H. Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J Bone Miner Res 2001, 16:448-456.
141. Kartsogiannis V., Udagawa N., Ng K.W., Martin T.J., Moseley J.M., Zhou H. Localization of parathyroid hormone-related protein in osteoclasts by in situ hybridization and immunohistochemistry. Bone 1998, 22:189-194.
142. Wen J., Xie D., Yao J., Zhang M., Bi J. Effect of cytokines on in vitro bone resorption by cells isolated from giant cell tumor of bone. Chin Med J (Engl) 1999, 112:443-447.
143. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998, 273:32347-32352.
144. Blair H.C., Teitelbaum S.L., Ghiselli R., Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989, 245:855-857.
145. Ek-Rylander B., Flores M., Wendel M., Heinegård D., Andersson G. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 1994, 269:14853-14856.
146. Janckila A.J., Yam L.T. Biology and clinical significance of tartrate-resistant acid phosphatases: new perspectives on an old enzyme. Calcif Tissue Int 2009, 85:465-483.
147. Rao V.H., Bridge J.A., Neff J.R., Schaefer G.B., Buehler B.A., Vishwanatha J.K., et al. Expression of 72kDa and 92kDa type IV collagenases from human giant-cell tumor of bone. Clin Exp Metastasis 1995, 13:420-426.
148. Wucherpfennig A.L., Li Y.P., Stetler-Stevenson W.G., Rosenberg A.E., Stashenko P. Expression of 92kD type IV collagenase/gelatinase B in human osteoclasts. J Bone Miner Res 1994, 9:549-556.
149. Ueda Y., Imai K., Tsuchiya H., Fujimoto N., Nakanishi I., Katsuda S., et al. Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am J Pathol 1996, 148:611-622.
150. Schoedel K.E., Greco M.A., Stetler-Stevenson W.G., Ohori N.P., Goswami S., Present D., et al. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in giant cell tumor of bone: an immunohistochemical study with clinical correlation. Hum Pathol 1996, 27:1144-1148.
151. Rao V.H., Singh R.K., Bridge J.A., Neff J.R., Schaefer G.B., Delimont D.C., et al. Regulation of MMP-9 (92kDa type IV collagenase/gelatinase B) expression in stromal cells of human giant cell tumor of bone. Clin Exp Metastasis 1997, 15:400-409.
152. Rao V.H., Singh R.K., Delimont D.C., Schaefer G.B., Bridge J.A., Neff J.R., et al. Interleukin-1β upregulates MMP-9 expression in stromal cells of human giant cell tumor of bone. J Interferon Cytokine Res 1999, 19:1207-1217.
153. Rao V.H., Singh R.K., Delimont D.C., Finnell R.H., Bridge J.A., Neff J.R., et al. Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Int J Oncol 1999, 14:291-300.
154. Cowan R.W., Mak I.W., Colterjohn N., Singh G., Ghert M. Collagenase expression and activity in the stromal cells from giant cell tumour of bone. Bone 2009, 44:865-871.
155. Si A.I., Huang L., Xu J., Kumta S.M., Wood D., Zheng M.H. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. J Cell Biochem 2003, 89:1154-1163.
156. Wuelling M., Delling G., Kaiser E. Differential gene expression in stromal cells of human giant cell tumor of bone. Virchows Arch 2004, 445:621-630.
157. Strauss L.G., Dimitrakopoulou-Strauss A., Koczan D., Bernd L., Haberkorn U., Ewerbeck V., et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med 2004, 45:1528-1535.
158. McQuibban G.A., Butler G.S., Gong J.H., Bendall L., Power C., Clark-Lewis I., et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001, 276:43503-43508.
159. McQuibban G.A., Gong J.H., Wong J.P., Wallace J.L., Clark-Lewis I., Overall C.M. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002, 100:1160-1167.
160. Xu J., Rodriguez D., Petitclerc E., Kim J.J., Hangai M., Moon Y.S., et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001, 154:1069-1079.
161. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
162. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169:681-691.
163. Chun T.H., Sabeh F., Ota I., Murphy H., McDonagh K.T., Holmbeck K., et al. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 2004, 167:757-767.
164. Stratman A.N., Saunders W.B., Sacharidou A., Koh W., Fisher K.E., Zawieja D.C., et al. Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices. Blood 2009, 114:237-247.
165. Nakamura H., Sato G., Hirata A., Yamamoto T. Immunolocalization of matrix metalloproteinase-13 on bone surface under osteoclasts in rat tibia. Bone 2004, 34:48-56.
166. Andersen T.L., del Carmen Ovejero M., Kirkegaard T., Lenhard T., Foged N.T., Delaissé J.M. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone 2004, 35:1107-1119.
167. Blavier L., Delaissé J.M. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 1995, 108(Pt 12):3649-3659.
168. Sato T., Foged N.T., Delaissé J.M. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J Bone Miner Res 1998, 13:59-66.
169. Zheng M.H., Fan Y., Wysocki S.J., Lau A.T., Robertson T., Beilharz M., et al. Gene expression of transforming growth factor-β1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration. Am J Pathol 1994, 145:1095-1104.
170. Deng S.J., Bickett D.M., Mitchell J.L., Lambert M.H., Blackburn R.K., Carter H.L., et al. Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library. J Biol Chem 2000, 275:31422-31427.
171. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176.
172. Holliday L.S., Welgus H.G., Fliszar C.J., Veith G.M., Jeffrey J.J., Gluck S.L. Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 1997, 272:22053-22058.
173. Holliday L.S., Welgus H.G., Hanna J., Lee B.S., Lu M., Jeffrey J.J., et al. Interstitial collagenase activity stimulates the formation of actin rings and ruffled membranes in mouse marrow osteoclasts. Calcif Tissue Int 2003, 72:206-214.
174. Mak I.W., Seidlitz E.P., Cowan R.W., Turcotte R.E., Popovic S., Wu W.C., et al. Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone. Hum Pathol 2010, 41:1320-1329.
175. Everts V., Delaissé J.M., Korper W., Niehof A., Vaes G., Beertsen W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 1992, 150:221-231.
176. Everts V., Delaissé J.M., Korper W., Beertsen W. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res 1998, 13:1420-1430.
177. Everts V., Delaissé J.M., Korper W., Jansen D.C., Tigchelaar-Gutter W., Saftig P., et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 2002, 17:77-90.
178. Olivera P., Perez E., Ortega A., Terual R., Gomes C., Moreno L.F., et al. Estrogen receptor expression in giant cell tumors of the bone. Hum Pathol 2002, 33:165-169.
179. Oursler M.J., Pederson L., Fitzpatrick L., Riggs B.L., Spelsberg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci U S A 1994, 91:5227-5231.
180. De Nayer P.P., Delloye C., Malghem J. Bone injury and late giant-cell tumor occurrence: a possible relation. A case report. Orthopedics 1987, 10:1279-1283.
181. Langer F., Pritzker K.P., Gross A.E., Shapiro I.I. Giant cell tumor associated with trauma. Clin Orthop Relat Res 1982, 164:245-248.
182. van Lochem E.G., van der Velden V.H., Wind H.K., te Marvelde J.G., Westerdaal N.A., van Dongen J.J. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom 2004, 60:1-13.
183. Athanasou N.A., Wells C.A., Quinn J., Ferguson D.P., Heryet A., McGee J.O. The origin and nature of stromal osteoclast-like multinucleated giant cells in breast carcinoma: implications for tumour osteolysis and macrophage biology. Br J Cancer 1989, 59:491-498.
184. Goldberg R.D., Michelassi F., Montag A.G. Osteoclast-like giant cell tumor of the pancreas: immunophenotypic similarity to giant cell tumor of bone. Hum Pathol 1991, 22:618-622.
185. Amann O., Meij B.P., Westerhof I., Kik M., Lumeij J.T., Schoemaker N.J. Giant cell tumor of the bone in a scarlet macaw (Ara macao). Avian Dis 2007, 51:146-149.
186. Imai T., Hibino N., Hayakawa K., Nakanowatari J., Fukuta T., Hosokawa S., et al. Giant cell tumor of bone in an aged Fischer 344 rat. Toxicol Pathol 1998, 26:802-805.
187. Ferreras M.C., Fuertes M., Perez V., Benavides J., Garcia-Pariente C., Reyes L.E., et al. Giant cell tumour of bone in a cat with extraskeletal metastases: pathological and immunohistochemical study. J Vet Med A Physiol Pathol Clin Med 2005, 52:225-229.
188. Berg J., Gliatto J.M., Wallace M.K. Giant cell tumor of the accessory carpal bone in a dog. J Am Vet Med Assoc 1990, 197:883-885.
189. Théoleyre S., Mori K., Cherrier B., Passuti N., Gouin F., Rédini F., et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer 2005, 5:123.
190. Cowan R.W., Ghert M., Singh G. T cells stimulate catabolic gene expression by the stromal cells from giant cell tumor of bone. Biochem Biophys Res Commun 2012, 419:719-723.
191. Haque A.U., Moatasim A. Giant cell tumor of bone: a neoplasm or a reactive condition?. Int J Clin Exp Pathol 2008, 1:489-501.
192. Aoki J., Moriya K., Yamashita K., Fujioka F., Ishii K., Karakida O., et al. Giant cell tumors of bone containing large amounts of hemosiderin: MR-pathologic correlation. J Comput Assist Tomogr 1991, 15:1024-1027.
193. Aoki J., Tanikawa H., Ishii K., Seo G.S., Karakida O., Sone S., et al. MR findings indicative of hemosiderin in giant-cell tumor of bone: frequency, cause, and diagnostic significance. AJR Am J Roentgenol 1996, 166:145-148.
194. Matsushige T., Nakaoka M., Yahara K., Kagawa K., Miura H., Ohnuma H., et al. Giant cell tumor of the temporal bone with intratumoral hemorrhage. J Clin Neurosci 2008, 15:923-927.